AxoGen
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfol...
Latest News
9 hours ago · fool.com
AxoGen: 3 Key Takeaways for Long-Term InvestorsAxoGen raised full-year 2026 revenue guidance to at least $290 million. Commercial payer coverage for Avance reached 96% of covered U.S. lives.
4 days ago · zacks.com
AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
7 days ago · seekingalpha.com
Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development TranscriptAxogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript
14 days ago · globenewswire.com
Axogen, Inc. to Participate in Multiple Upcoming Investor ConferencesALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:
18 days ago · seekingalpha.com
Axogen: Taking The Friction Out Of Nerve RepairAxogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next decade. Q3 2026 saw 26% revenue growth, 45% adjusted EBITDA growth, and operating leverage outpacing dilution, with guidance for at least $290M in 2026 sales and 73%+ gross margin. The $200M BioCircuit (NerveTape) acquisition eliminates technical barriers for surgeons, expands the addressable market, and is accretive at 5.9x expected 2027 sales.
19 days ago · zacks.com
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
19 days ago · marketbeat.com
AxoGen Q3 Earnings Call HighlightsAxoGen NASDAQ: AXGN reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets. The company also raised its full-year revenue outlook following the October acquisition of BioCircuit and said it plans to begin prostate nerve reconstruction market-development activities in 2027.
20 days ago · seekingalpha.com
Axogen, Inc. (AXGN) Q3 2026 Earnings Call TranscriptAxogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript
20 days ago · zacks.com
AxoGen (AXGN) Beats Q3 Earnings and Revenue EstimatesAxoGen (AXGN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.
20 days ago · globenewswire.com
Axogen, Inc. Reports Third Quarter 2026 Financial ResultsRaises Full Year Revenue Guidance to at Least 29% Growth or $290 million Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AXGN